ArticleScientific reports2026
Rapid and ultrasensitive detection of telomerase activity in clinical samples using a PCR-free enzymatic assay.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Telomerase, a critical biomarker for cancer diagnosis, necessitates the development of convenient, efficient, and highly sensitive detection methods. Distinct from conventional nucleic acid amplification techniques such as PCR, LAMP, or RCA, this method achieves signal amplification through Endo IV-mediated enzymatic turnover. A rationally designed probe containing an abasic site specifically hybridizes with telomerase-synthesized (TTAGGG)n repeats, enabling precise Endo IV recognition and cleavage that separates a fluorophore-quencher pair for fluorescence signal generation. Cyclic signal amplification is achieved through probe displacement-driven enzymatic turnover. Following systematic optimization (abasic site at nucleotide 11, 500 nM probe, 0.1 U/µL Endo IV), the method exhibits a broad linear range (5-2000 cells) and high sensitivity with a detection limit of 5 HeLa cells. It also demonstrates excellent precision (intra-day RSD: 1.31-1.75%; inter-day RSD: 4.60%), high accuracy (spiked recovery: 97.3-102.1%), and robust anti-interference capability in complex matrices. The assay distinguishes telomerase‑positive cancer cells (NB4, K562, A549, MCF-7, HeLa) from telomerase‑negative normal cells (MRC-5), and correlates well with a commercial ELISA kit. In clinical tissue samples, it differentiated gastric carcinoma from adjacent normal tissues. Collectively, this study provides an analytical platform for telomerase activity detection with potential applications in cancer research and diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.